DocWire News Editors

DocwireNews

A San Diego based developer, Dthera Sciences, has recently been granted Breakthrough Device designation from the FDA for a digital therapeutic device for Alzheimer&rsquo;s. The device, DTHR-ALZ, delivers therapy through a custom tablet with a front-facing camera that displays content such as photos of loved ones and memories uploaded by the patient&rsquo;s family. As the patient enjoys the memories, an AI system collects data through the camera to adjust the content to the viewers&rsquo; emotions.By the 21st Century Cures Act, the Breakthrough Devices Program aims to streamline new medical technologies that provide improved treatment and diagnosis options for diseases that lack therapeutic options. This designation does not indicate clearance; however, the FDA works with those sponsoring the device to reduce the time and money spent seeking approval.This device follows Pear Therapeutic&rsquo;s reset as a pioneering digital therapeutic product that received this designation. DTHR-ALZ is an intervention &ldquo;intended to mitigate the symptoms of agitation and depression associated with major neurocognitive disorder of the Alzheimer&rsquo;s type,&rdquo; as per the proposed instruction for use.&ldquo;Obviously I&rsquo;m biased, but I think this is great move by the FDA because it shows that they care for these patients and their families,&rdquo; said Dthera Sciences CEO Edward Cox. &ldquo;To our knowledge, we&rsquo;re the only non-pharmalogical, non-pharmaceutical product to ever be given this designation for the Alzheimer&rsquo;s indication. That means that they&rsquo;re looking to make a difference with this public health crisis, as Alzheimer&rsquo;s is the only top-ten, leading cause of death that has no cures and can&rsquo;t be treated.&rdquo;Cox stated that the devices technology has been in the development process for approximately four years and is similar to ReminX, Dthera Sciences product that gives seniors images of their past to alleviate anxiety and solitude. Using this products development strategy and studies published of reminiscent therapy, a trail was conducted with the University of California San Diego to test DTHR-ALZ&rsquo;s efficacy. Cox said that after these trials, Dthera had enough confidence to bring the project to the FDA.&ldquo;For us, we have every reason to believe that this will be successful,&rdquo; Cox said. &ldquo;What we want to do is work closely with the FDA to guide a product that can consistently, repeatedly, and importantly, proven in a clinical trial, bring these patients back from the edge.&rdquo;<blockquote class="twitter-tweet" data-lang="en">
<a href="https://twitter.com/DtheraSciences?ref_src=twsrc%5Etfw">@DtheraSciences</a> Receives FDA Breakthrough Device Designation For Its Alzheimer&rsquo;s Focused Development-Stage Product &ldquo;DTHR-ALZ&rdquo; <a href="https://t.co/OK4enECsZk">https://t.co/OK4enECsZk</a>
&mdash; Dthera Sciences (@DtheraSciences) <a href="https://twitter.com/DtheraSciences/status/1032656170421432321?ref_src=twsrc%5Etfw">August 23, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Source:&nbsp;<a href="https://www.mobihealthnews.com/content/fda-grants-digital-therapeutic-alzheimers-symptoms-breakthrough-device-designation">MobiHealthNews</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

FDA Grants Breakthrough Designation for Alzheimer's Digital Therapeutic

Future of Medicine

A San Diego based developer, Dthera Sciences, has recently been granted Breakthrough Device designation from the FDA for a digital therapeutic device for Alzheimer’s. The ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe